COVID-19 mRNA Vaccines are Safe and Effective

Ciprian Silaghi¹, Madalina Bordea², Gina Klein³, Corina Tritean³, Genel Sur^{3, 4}, Cornel Aldea^{3, 4}, Gabriel Samasca^{3, 5,} , Teodora-Larisa Timis⁶, Ioan-Alexandru Florian⁷, Peter Makovicky⁸, Pavol Makovicky⁹ and Kvetoslava Rimarova¹⁰

¹Department of Biochemistry, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

²Department of Microbiology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

³Emergency Hospital for Children, Cluj-Napoca, Romania

⁴Department of Pediatrics II, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

⁵Department of Immunology, Iuliu Hatieganu University of Medicine and Pharmacy

⁶Department of Physiology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

⁷Department of Neurosurgery, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

⁸Biomedical Research Center of the Slovak Academy of Sciences, Institute of Experimental Oncology, Bratislava, Slovak Republic

⁹Department of Biology, Faculty of Education, Selye Janos University, Komarno, Slovak Republic

¹⁰0Department of Public Health and Hygiene, Faculty of Medicine, P. J. Šafárik University, Košice, Slovak Republic

Cite this paper:
Ciprian Silaghi, Madalina Bordea, Gina Klein, Corina Tritean, Genel Sur, Cornel Aldea, Gabriel Samasca, Teodora-Larisa Timis, Ioan-Alexandru Florian, Peter Makovicky, Pavol Makovicky and Kvetoslava Rimarova. COVID-19 mRNA Vaccines are Safe and Effective. International Journal of Celiac Disease. 2021; 9(3):103-106. doi: 10.12691/ijcd-9-3-4

Abstract

mRNA vaccines are a novelty in the medical world. The researchers created these vaccines in a short time, which led to many question marks. In this article, we have analyzed the perception of the world's countries on these vaccines.

Keywords:
mRNA vaccines new vaccines causes of mistrust

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Samasca G. The COVID-19 Vaccination Debate: Should Patients with Celiac Disease be Vaccinated with COVID-19 Vaccine? International Journal of Celiac Disease. 2021; 9(1): 1-2.
[2]	Verbeke R, Lentacker I, De Smedt SC, Dewitte H. The dawn of mRNA vaccines: The COVID-19 case. J Control Release. 2021: S0168-3659(21)00154-1.
[3]	Diotallevi F, Campanati A, Radi G, Martina E, Rizzetto G, Barbadoro P, D'Errico MM, Offidani A. VACCINATION AGAINST SARS-COV-2 and PSORIASIS: the three things every dermatologist should know. J Eur Acad Dermatol Venereol. 2021; 35(7):e428-e430.
[4]	Dyer O. Covid-19: Moderna and Pfizer vaccines prevent infections as well as symptoms, CDC study finds. BMJ. 2021; 373: n888.
[5]	Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics (Basel). 2021; 11: 579.
[6]	Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, Olsho LEW, Caban-Martinez AJ, Fowlkes A, Lutrick K, Kuntz JL, Dunnigan K, Odean MJ, Hegmann KT, Stefanski E, Edwards LJ, Schaefer-Solle N, Grant L, Ellingson K, Groom HC, Zunie T, Thiese MS, Ivacic L, Wesley MG, Lamberte JM, Sun X, Smith ME, Phillips AL, Groover KD, Yoo YM, Gerald J, Brown RT, Herring MK, Joseph G, Beitel S, Morrill TC, Mak J, Rivers P, Harris KM, Hunt DR, Arvay ML, Kutty P, Fry AM, Gaglani M. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70: 495-500.
[7]	Nel AE, Miller JF. Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. ACS Nano. 2021; 15(4): 5793-5818.
[8]	Kuzmina A, Khalaila Y, Voloshin O, Keren-Naus A, Boehm-Cohen L, Raviv Y, Shemer-Avni Y, Rosenberg E, Taube R. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe. 2021: S1931-3128(21)00136-0.
[9]	Lombardi A, Bozzi G, Ungaro R, Villa S, Castelli V, Mangioni D, Muscatello A, Gori A, Bandera A. Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results. Front Immunol. 2021; 12: 657711.
[10]	Brockman MA, Mwimanzi F, Sang Y, Ng K, Agafitei O, Ennis S, Lapointe H, Young L, Umviligihozo G, Burns L, Brumme C, Leung V, Montaner JSG, Holmes D, DeMarco M, Simons J, Niikura M, Pantophlet R, Romney MG, Brumme ZL. Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine. medRxiv. 2021: 2021.03.17.21253773.
[11]	Gobbi F, Buonfrate D, Moro L, Rodari P, Piubelli C, Caldrer S, Riccetti S, Sinigaglia A, Barzon L. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection. Viruses. 2021; 13: 422.
[12]	Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, Wolf T, Nadler V, Ben-Tov A, Kuint J, Gazit S, Patalon T, Chodick G, Kishony R. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021; 27(5):790-792.
[13]	Webb Hooper M, Nápoles AM, Pérez-Stable EJ. No Populations Left Behind: Vaccine Hesitancy and Equitable Diffusion of Effective COVID-19 Vaccines. J Gen Intern Med. 2021: 1-4.
[14]	Bordea M, Klein G, Salanta L, Muntean D, Urda F, Dolha A, Samsudean C, Trifan V, Ples A, Pop V, Hosu L, Danyi A, Piscoran R, Rus R, Rus P, Lutai C, Copaciu A, Tritean C, Nylas C, Silaghi C, Man S, Aldea C, Samasca G. COVID-19 Pandemic an Update for Celiac Community. International Journal of Celiac Disease 8(2): 68-75.
[15]	Raftopoulos V, Iordanou S, Katsapi A, Dedoukou X, Maltezou HC. A comparative online survey on the intention to get COVID-19 vaccine between Greek and Cypriot healthcare personnel: is the country a predictor? Hum Vaccin Immunother. 2021: 1-8.
[16]	Batty GD, Deary IJ, Fawns-Ritchie C, Gale CR, Altschul D. Pre-pandemic Cognitive Function and COVID-19 Vaccine Hesitancy: Cohort Study. medRxiv. 2021: 2021.03.16.21253634.
[17]	Stern MF, Piasecki AM, Strick LB, Rajeshwar P, Tyagi E, Dolovich S, Patel PR, Fukunaga R, Furukawa NW. Willingness to Receive a COVID-19 Vaccination Among Incarcerated or Detained Persons in Correctional and Detention Facilities - Four States, September-December 2020. MMWR Morb Mortal Wkly Rep. 2021; 70: 473-477.
[18]	Bourhanbour AD, Ouchetto O. Morocco achieves the highest COVID-19 vaccine rates in Africa in the first phase: what are reasons for its success? J Travel Med. 2021: 28(4): taab040.
[19]	Salmon DA, Dudley MZ, Brewer J, Kan L, Gerber JE, Budigan H, Proveaux TM, Bernier R, Rimal R, Schwartz B. COVID-19 vaccination attitudes, values and intentions among United States adults prior to emergency use authorization. Vaccine. 2021: S0264-410X(21)00315-7.
[20]	[No authors listed]. COVID-19 Roundup. Am J Nurs. 2021; 121: 18.
[21]	Liu R, Zhang Y, Nicholas S, Leng A, Maitland E, Wang J. COVID-19 Vaccination Willingness among Chinese Adults under the Free Vaccination Policy. Vaccines (Basel). 2021; 9: 292.
[22]	Chew NWS, Cheong C, Kong G, Phua K, Ngiam JN, Tan BYQ, Wang B, Hao F, Tan W, Han X, Tran BX, Hoang MT, Pham HQ, Vu GT, Chen Y, Danuaji R, Rn K, Rv M, Talati K, Ho CS, Sharma AK, Ho RC, Sharma VK. An Asia-Pacific study on healthcare worker's perception and willingness to receive COVID-19 vaccination. Int J Infect Dis. 2021: S1201-9712(21)00287-3.
[23]	Dela Cruz MDM, Mendoza AJM, Gueco GEA, Maghinang CJMP, Gopez JMW Transparency of the national government as key in promoting the rollout of COVID-19 vaccines. J Public Health (Oxf). 2021: 43(2): e381-e382.
[24]	Alvarado-Socarras JL, Vesga-Varela AL, Quintero-Lesmes DC, Fama-Pereira MM, Serrano-Diaz NC, Vasco M, Carballo-Zarate V, Zambrano LI, Paniz-Mondolfi A, Rodriguez-Morales AJ. Perception of COVID-19 Vaccination Amongst Physicians in Colombia. Vaccines (Basel). 2021; 9: 287.
[25]	Amiri A. Role of social distancing in tackling COVID-19 during the first wave of pandemic in Nordic region: Evidence from daily deaths, infections and needed hospital resources. Int J Nurs Sci. 2021: 10; 8(2): 145-151.
[26]	Benis A, Seidmann A, Ashkenazi S. Reasons for Taking the COVID-19 Vaccine by US Social Media Users. Vaccines (Basel). 2021; 9: 315.
[27]	Machida M, Nakamura I, Kojima T, Saito R, Nakaya T, Hanibuchi T, Takamiya T, Odagiri Y, Fukushima N, Kikuchi H, Amagasa S, Watanabe H, Inoue S. Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic. Vaccines (Basel). 2021; 9: 210.
[28]	Biasio LR, Bonaccorsi G, Lorini C, Mazzini D, Pecorelli S. Italian Adults' Likelihood of Getting COVID-19 Vaccine: A Second Online Survey. Vaccines (Basel). 2021; 9: 268.
[29]	Malesza M, Wittmann E. Acceptance and Intake of COVID-19 Vaccines among Older Germans. J Clin Med. 2021; 10: 1388.
[30]	Lunsky Y, Kithulegoda N, Thai K, Benham JL, Lang R, Desveaux L, Ivers NM. Beliefs regarding COVID-19 vaccines among Canadian workers in the intellectual disability sector prior to vaccine implementation. J Intellect Disabil Res. 2021; 65(7): 617-625.
[31]	Vallis M, Glazer S. Protecting Individuals Living with Overweight and Obesity: Attitudes and Concerns Towards COVID-19 Vaccination in Canada. Obesity (Silver Spring). 2021; 29(7): 1128-1137.
[32]	Szmyd B, Karuga FF, Bartoszek A, Staniecka K, Siwecka N, Bartoszek A, Błaszczyk M, Radek M. Attitude and Behaviors towards SARS-CoV-2 Vaccination among Healthcare Workers: A Cross-Sectional Study from Poland. Vaccines (Basel). 2021; 9: 218.
[33]	Alfageeh EI, Alshareef N, Angawi K, Alhazmi F, Chirwa GC. Acceptability of a COVID-19 Vaccine among the Saudi Population. Vaccines (Basel). 2021; 9: 226.
[34]	Sallam M, Dababseh D, Eid H, Hasan H, Taim D, Al-Mahzoum K, Al-Haidar A, Yaseen A, Ababneh NA, Assaf A, Bakri FG, Matar S, Mahafzah A. Low COVID-19 Vaccine Acceptance Is Correlated with Conspiracy Beliefs among University Students in Jordan. Int J Environ Res Public Health. 2021; 18: 2407.
[35]	Jackson SE, Paul E, Brown J, Steptoe A, Fancourt D. Negative vaccine attitudes and intentions to vaccinate against Covid-19 in relation to smoking status: a population survey of UK adults. Nicotine Tob Res. 2021; 18; 23(9): 1623-1628.
[36]	Ceulemans M, Foulon V, Panchaud A, Winterfeld U, Pomar L, Lambelet V, Cleary B, O'Shaughnessy F, Passier A, Richardson JL, Allegaert K, Nordeng H. Vaccine Willingness and Impact of the COVID-19 Pandemic on Women's Perinatal Experiences and Practices-A Multinational, Cross-Sectional Study Covering the First Wave of the Pandemic. Int J Environ Res Public Health. 2021; 18: 3367.
[37]	Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, Medina Baez A, Shook LL, Cvrk D, James K, De Guzman R, Brigida S, Diouf K, Goldfarb I, Bebell LM, Yonker LM, Fasano A, Rabi SA, Elovitz MA, Alter G, Edlow AG. COVID-19 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021: S0002-9378(21)00187-3.
[38]	Benotmane I, Gautier-Vargas G, Cognard N, Olagne J, Heibel F, Braun-Parvez L, Martzloff J, Perrin P, Moulin B, Fafi-Kremer S, Caillard S. Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int. 2021: S0085-2538(21)00348-3.
[39]	Silberman E. Serious COVID-19 Vaccine Reactions are Rare, Says New CDC Report. ABD News via Yahoo News; 2021.
[40]	Giavina-Bianchi P, Kalil J. May polyethylene glycol be the cause of anaphylaxis to mRNA COVID-19 vaccines? World Allergy Organ J. 2021: 100532.
[41]	Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A, Assimakopoulos SF, Gogos C, Kouni SN, Kounis GN, Calogiuri G, Hung MY. Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines (Basel). 2021; 9: 221.
[42]	Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus. 2021; 13: e13426.
[43]	Shi Y, Guo M, Yang W, Liu S, Zhu B, Yang L, Yang C, Liu C. Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases? Expert Rev Vaccines. 2021; 20(4): 375-383.
[44]	Lu L, Xiong W, Mu J, Zhang Q, Zhang H, Zou L, Li W, He L, Sander JW, Zhou D. The potential neurological effect of the COVID-19 vaccines: A review. Acta Neurol Scand. 2021; 144(1): 3-12.
[45]	Chilimuri S, Mantri N, Gongati S, Zahid M, Sun H. COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab. Vaccines (Basel). 2021; 9: 219.
[46]	Deva Priya SA, Kavitha S, Venugopal P, Sriram DK, George M. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges. Clin Drug Investig. 2021:1-11.
[47]	Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP, Petrakis D, Bakerly ND. Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. Life (Basel). 2021; 11: 249.
[48]	Hiller N, Goldberg SN, Cohen-Cymberknoh M, Vainstein V, Simanovsky N. Lymphadenopathy Associated With the COVID-19 Vaccine. Cureus. 2021; 13: e13524.
[49]	Granata V, Fusco R, Setola SV, Galdiero R, Picone C, Izzo F, D'Aniello R, Miele V, Grassi R, Grassi R, Petrillo A. Lymphadenopathy after BNT162b2 Covid-19 Vaccine: Preliminary Ultrasound Findings. Biology (Basel). 2021; 10: 214.
[50]	Malayala SV, Mohan G, Vasireddy D, Atluri P. Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine. Cureus. 2021; 13: e14099.
[51]	Ackerman M, Henry D, Finon A, Binois R, Esteve E. Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021; 35(7): e423-e425.
[52]	Li X, Ostropolets A, Makadia R, Shaoibi A, Rao G, Sena AG, Martinez-Hernandez E, Delmestri A, Verhamme K, Rijnbeek PR, Duarte-Salles T, Suchard M, Ryan P, Hripcsak G, Prieto-Alhambra D. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study. medRxiv. 2021: 2021. 03.25. 21254315.